Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 Women
Authors:
- 1 February 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (2) , 857-862
Abstract
According to the European AIDS Clinical Society, tenofovir disoproxil fumarate can be used in HIV-infected pregnant women if started prior to pregnancy, although no data are available on the pharmacokinetics of tenofovir (TFV) during pregnancy. The aim of this study was to describe TFV pharmacokinetics in HIV-infected women and to evaluate the effect of pregnancy on TFV disposition. Samples were collected according to a therapeutic drug monitoring in 186 women, including 46 pregnant women treated with TFV and retrospectively analyzed by a population approach. TFV pharmacokinetics were ascribed to an open two-compartment model with linear absorption and elimination. The mean population parameter estimates (between-subject variability) were as follows: absorption rate constant, 0.56 h −1 ; elimination clearance, 59.9 liters h −1 (0.436); central volume of distribution, 552 liters (1.96); intercompartmental clearance, 172 liters/h; and peripheral volume of distribution, 1,390 liters. Pregnant women had a 39% higher apparent clearance compared to nonpregnant women. Apparent clearance significantly decreased with age. In order to obtain an exposure similar to the known exposure in adults and guarantee similar trough concentrations ( C min ) as observed in adults, an increase in the TFV dose should be considered for women from the second trimester to delivery.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their InfantsAntimicrobial Agents and Chemotherapy, 2011
- Tenofovir disoproxil fumarate in pregnancy and prevention of mother‐to‐child transmission of HIV‐1: is it time to move on from zidovudine?HIV Medicine, 2009
- Population Pharmacokinetics of Tenofovir in HIV-1-Infected Pregnant Women and Their Neonates (ANRS 12109)Clinical Pharmacology & Therapeutics, 2008
- Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy VolunteersThe Journal of Clinical Pharmacology, 2007
- Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir MesylateAntimicrobial Agents and Chemotherapy, 2005
- Maximum likelihood estimation in nonlinear mixed effects modelsComputational Statistics & Data Analysis, 2005
- Pregnancy-Induced Changes in PharmacokineticsClinical Pharmacokinetics, 2005
- Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detectionJournal of Chromatography B, 2002
- Ways to Fit a PK Model with Some Data Below the Quantification LimitJournal of Pharmacokinetics and Pharmacodynamics, 2001
- Overview: Kidney Function in Pregnant WomenAmerican Journal of Kidney Diseases, 1987